This CPB is revised to state that denosumab (Prolia) is considered medically necessary for treatment to increase bone mass in men at high-risk for fracture receiving androgen deprivation therapy for prostate cancer. (The previous version of the CPB limited coverage only to men with prostate cancer that was not metastatic.)